Tracleer digital ulcer data

Actelion (SWX:ATLN) said that in its 16-week placebo-controlled U.S. and European RAPIDS-1 study in 122 scleroderma patients, Tracleer bosentan met the primary endpoint of preventing ischemic digital ...